Daniel R. Hart
2022
In 2022, Daniel R. Hart earned a total compensation of $2.1M as Chief Financial Officer at Peregrine Pharmaceuticals, a 53% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $320,780 |
|---|---|
| Salary | $430,000 |
| Stock Awards | $1,266,100 |
| Other | $50,328 |
| Total | $2,067,208 |
Hart received $1.3M in stock awards, accounting for 61% of the total pay in 2022.
Hart also received $320.8K in non-equity incentive plan, $430K in salary and $50.3K in other compensation.
Rankings
In 2022, Daniel R. Hart's compensation ranked 1,709th out of 5,756 executives tracked by ExecPay. In other words, Hart earned more than 70.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,709 out of 5,756 | 70th |
Division Manufacturing | 893 out of 3,133 | 72nd |
Major group Chemicals And Allied Products | 360 out of 1,419 | 75th |
Industry group Drugs | 329 out of 1,320 | 75th |
Industry Pharmaceutical Preparations | 235 out of 966 | 76th |
Source: SEC filing on August 29, 2022.
Hart's colleagues
We found two more compensation records of executives who worked with Daniel R. Hart at Peregrine Pharmaceuticals in 2022.
News
Peregrine Pharmaceuticals CEO Nicholas Green's 2023 pay rises 5% to $6.5M
August 28, 2023
Peregrine Pharmaceuticals CEO Nicholas Green's 2022 pay jumps 117% to $6.2M
August 29, 2022
Peregrine Pharmaceuticals CEO Nicholas Green receives $2.8M in 2021
August 27, 2021
Peregrine Pharmaceuticals General Counsel Mark Ziebell's 2020 pay jumps 124% to $1.1M
August 27, 2020
Peregrine Pharmaceuticals CEO Roger Lias' 2019 pay jumps 25% to $880K
August 21, 2019